Our vision is to develop siRNA to restore gene networks for major tissues implicated in complex disease.
Meet the Leadership Team
JOHN HOEKMAN
PhD, Co-founder & CEO
Founder, CSO, and CEO Impel Pharma. Brought his PhD invention to FDA approval for Trudhesa® for migraines. Inventor on >100 patents. PhD in Pharmaceutics at Univ. of Washington.
JANINE SENGSTACK
PhD, Co-founder & CSO
First to show repressing single transcription factor can restore gene expression to a healthy state (PNAS 2026). Hillblom Fellow. PhD in Cellular Aging at UCSF.
ROB CAHILL
Co-founder, COO & CBO
UCSF bioinformatics & machine learning. Founder & CEO at Jhana, acquired by FranklinCovey (NYSE: FC). EVP Product & Client Success at FranklinCovey. McKinsey. Stanford.
YI JIN
PhD, VP of siRNA Therapeutic Development
20 years of siRNA experience. Previously, Scientific Director of siRNA of Johnson & Johnson Innovative Medicine.
Our Team
CHARU REDDY
PhD, Director, Preclinical & Translational Development
10+ years in metabolism and preclinical biotech. Postdoc at Harvard Medical School. PhD in rodent metabolism.
KATIE GJONI
PhD, Bioinformatics Data Scientist
Computational biologist with experience in ML pipeline development, genetic variant modeling and multi-omics. Prev. Genentech. PhD UCSF & Gladstone.
KELSEY SATTERLY
PhD, VP of Early Clinical Development
15+ years experience in biotech, early phase program leadership, and clinical development. PhD in medicinal chemistry at University of Washington.
L’ERIN MOORE
Scientist, Preclinical
10+ years of preclinical research at Gilead and Northwestern University.
SETH PAULSON
Software Engineer, RESET Platform
15 years of full-stack software development. Creator and lead developer at Biolearn, open source library for biomarkers of aging.
JIASHUN ZHENG
PhD, Bioinformatics Data Science (contract)
UCSF Professional Researcher. Collaborator, co-inventor and co-lead author
with Dr. Sengstack and Dr. Li.
KEMI OLUGEMO
MD, FAAN, Clinical/Medical
Former Chief Medical Officer at Korro Bio
LAUREN MELTON
MS, Regulatory
Former drug development and regulatory at Alnylam, Vertex
HAO LI
PhD, Co-founder of Junevity & UCSF Professor
UCSF Prof. of Biochemistry & Biophysics. Director of UCSF Hillblom Center for Biology of Aging. Focus on cellular/molecular mechanisms of aging, human genetics, and bioinformatics.
Our Advisors
JOHN BAMFORTH
PhD, Former CMO at Eli Lilly
RACHEL MEYERS
PhD, Former SVP Research at Alnylam
STUART MILSTEIN
PhD, Former Scientific Director at Alnylam
LAURENCE REID
PhD, Former Chief Business Officer at Alnylam
SAMUEL KLEIN
MD, Washington University, Diabetes Research Center
ANDREW FRALEY
PhD, Co-founder at Korro Bio, Judo Bio
AIMEE KAO
MD/PhD, UCSF Professor, Neurology, Memory & Aging Center
REZA ABBASI ASL
PhD, UCSF Professor, Boinformatics & AI, Weill Institute for Neurosciences
CARL DAMBKOWSKI
MD, Chief Medical Officer, Apogee Therapeutics
Our Investors
Junevity’s investors include Goldcrest Capital (lead), Godfrey Capital (lead), biotech veterans, doctors, tech entrepreneurs and hedge fund managers.
Global spend on healthcare due to age-related diseases exceeds $5 trillion annually. We can change this.
